I am Dr. Mojtaba Mafi M.D., Medical Doctor/ Physician, graduated from Tehran university, School of Medicine with honor. I studied in neurosurgery ward and graduated with A score with thesis on Meningioma Brain Tumor during 6 years. With continuing my practice with special consideration on psychosomatic disorders, I completed many post graduate courses on health psychology, addiction medicine, sexual disorders therapy successfully. I passed many post graduate courses in Neuro, approved by Medical sciences university. As well, I have been passed post graduate courses on Nutrition, Gastroenterology and hepatology, Obesity treatment and diabetes approved by Tehran University of Medical sciences. I successfully passed more than 10 programs with certificates and membership in Iranian Association of Gastroenterology and Hepatology I published reviews for articles on Brain Tumor Immunotherapy, CNS Tumor Guideline and Alzheimer disease in Elsevier and Kudos. My review on Alzheimer's disease article with specific DOI, was published in American Physiological Society. I have been invited by editor in chief of American Journal of Translational Medicine, to participate at International Conference of Translational Medicine, in Hawaii

fatty live, metabolic disorders

Sam Vaknin is the author of Malignant Self-love: Narcissism Revisited and other books about personality disorders. His work is cited in hundreds of books and dozens of academic papers. He spent the past 6 years developing Cold Therapy: a treatment modality for Narcissistic Personality Disorder (NPD). Over the years, with dozens of volunteers, he found that it was effective with clients suffering from a major depressive episode as well.

Personality disorders

Prior to founding Alzheon, Dr. Tolar held executive positions in life sciences companies, where he established and grown new companies, business areas and product opportunities. Dr. Tolar served as President & CEO of Knome, Inc., President & CEO at NormOxys, Inc., and as Chief Scientific Officer and Chief Business Officer at CoMentis, Inc., where he built the first clinical beta secretase inhibitor platform and negotiated a deal for the program for $1.1 billion with Astellas Pharma in 2008. Dr. Tolar held a variety of clinical development and business leadership positions at Pfizer, where he was instrumental in a wide range of business transactions, including acquisition of Rinat Neuroscience for $500 million in 2006, and directed programs through all stages of clinical development and FDA approval including NDA filings. During his academic career, Dr. Tolar served as an Assistant Professor in the Department of Neurology at Yale University School of Medicine. Dr. Tolar was recognized as one of the Top 100 Most Influential People in the world of drug development and manufacture by The Medicine Maker Magazine’s Power Lists for 2016, 2017 and 2018

Alzheimer’s disease,neurodegenerative disorders,The Amyloid Cascade Hypothesis